Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Dig Liver Dis ; 54(1): 76-83, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34244110

RESUMO

BACKGROUND: Anti-TNFα represent one of the main treatment approaches for the management of inflammatory bowel diseases (IBD). Therefore,the evaluation of their treatment patterns over time provides valuable insights about the clinical value of therapies and associated costs. AIMS: To assess the treatment patterns with the first anti-TNFα in IBD. METHODS: Retrospective, observational study. RESULTS: 310 IBD patients were analyzed along a 5-year follow-up period. 56.2% of Crohn's disease (CD) patients started with adalimumab (ADA), while 43.8% started with infliximab (IFX). 12.9% of ulcerative colitis (UC) patients initiated with ADA, while 87.1% initiated with IFX. Treatment intensification was required in 28.9% of CD and 37.1% of UC patients. Median time to treatment intensification was shorter in UC than in CD (5.3 vs. 14.3 months; p = 0.028). Treatment discontinuation due to reasons other than remission were observed in 40.7% of CD and 40.5% of UC patients, although, in UC patients there was a trend to lower discontinuation rates with IFX (36.6%) than with ADA (66.7%). Loss of response accounted for approximately one-third of discontinuations, in both CD and UC. CONCLUSIONS: Around one-third of IBD biologic-naive patients treated with an anti-TNFα required treatment intensification (earlier in UC) and around 40% discontinued the anti-TNFα due to inappropriate disease control.


Assuntos
Adalimumab/uso terapêutico , Colite Ulcerativa/tratamento farmacológico , Doença de Crohn/tratamento farmacológico , Infliximab/uso terapêutico , Inibidores do Fator de Necrose Tumoral/uso terapêutico , Adulto , Feminino , Seguimentos , Humanos , Quimioterapia de Indução/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Suspensão de Tratamento/estatística & dados numéricos
2.
J Epidemiol Community Health ; 51(5): 526-30, 1997 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-9425463

RESUMO

OBJECTIVE: To estimate the effectiveness of influenza vaccine in preventing hospital admission for pneumonia in non-institutionalised elderly people. DESIGN: This was a case-control study. SETTING: All three public hospitals in the Castellón area of Spain. PARTICIPANTS: Cases were people aged 65 or more not living in an institution who were admitted to hospital for pneumonia between November 15, 1994 and March 31, 1995. Each case was matched with two sex matched control subjects aged 65 years or older admitted to hospital in the same week for acute abdominal surgical conditions or trauma. The sampling of incident cases was consecutive. Eighty three cases and 166 controls were identified and included in the study. MEASUREMENTS: Trained interviewers completed a questionnaire for each subject on the vaccination status, smoking habits, previous diseases, health care use, social contacts, family background, the vaccination status of the family carer, home characteristics, and socioeconomic status. RESULTS: The adjusted odds ratio of the influenza vaccination preventing admission to hospital for pneumonia was 0.21 (95% confidence interval 0.09, 0.55). The variables which best explained the risk of being a case were age, intensity of social contacts, health care use, previous diseases, and the existence of a vaccinated family carer. CONCLUSIONS: Influenza vaccination reduced significantly hospital admissions for pneumonia in non-institutionalised elderly people.


Assuntos
Vacinas contra Influenza , Admissão do Paciente/estatística & dados numéricos , Pneumonia Viral/prevenção & controle , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Cuidadores , Estudos de Casos e Controles , Feminino , Hospitais/estatística & dados numéricos , Humanos , Masculino , Pneumonia Viral/epidemiologia , Fatores de Risco , Espanha/epidemiologia
3.
An Esp Pediatr ; 25(5): 363-6, 1986 Nov.
Artigo em Espanhol | MEDLINE | ID: mdl-3028220

RESUMO

Authors report three cases of congenital mesoblastic nephroma. In two of them, diagnosis was neonatal, while the third was made at the 3rd-month. They discuss diagnostic procedures employed as well as pathological findings. Presence of a mass was the first clinical sign in all three cases. Nephrectomy was the only treatment employed, with favourable outcome.


Assuntos
Neoplasias Renais/congênito , Tumor de Wilms/congênito , Feminino , Humanos , Lactente , Recém-Nascido , Neoplasias Renais/diagnóstico por imagem , Neoplasias Renais/patologia , Masculino , Radiografia , Tumor de Wilms/diagnóstico por imagem , Tumor de Wilms/patologia
5.
Chemotherapy ; 23 Suppl 1: 315-23, 1977.
Artigo em Inglês | MEDLINE | ID: mdl-832530

RESUMO

Reference is made to the results obtained in 24 children, from 11 months to 12 years, affected with acute pneumopathies and treated with fosfomycin with a dosage of 200 mg/kg/day. In all cases a clinical, radiological, biological and bacteriological study was carried out. At the same time, levels of fosfomycin in plasma and sputum were checked every 5 days during the course of treatment. In the 4 cases of pleurisy the level of antibiotic in the pleural liquid was also checked. The concentration of fosfomycin in the sputum gives very variable results with average values oscillating between 16.5 and 23.4% of the plasmatic level respectively at the beginning and end of treatment, a cumulative effect of the antibiotic being observed. Concentration in pleural liquid oscillates between 39 and 50%. The clinical, radiological and biological evolution has been favourable iin 21 cases, unfavourable in two cases and in one case treatment had to be suspended because of the apparition of a cutaneous necrosis. Apart from this case no notable toxic effects were observed. Children do not support intramuscular injections very well and intravenous injections often cause phlebitis.


Assuntos
Antibacterianos/uso terapêutico , Fosfomicina/uso terapêutico , Infecções Respiratórias/tratamento farmacológico , Bronquite/tratamento farmacológico , Criança , Pré-Escolar , Avaliação de Medicamentos , Fosfomicina/efeitos adversos , Fosfomicina/metabolismo , Humanos , Lactente , Pleura/metabolismo , Pleurisia/tratamento farmacológico , Pneumonia/tratamento farmacológico , Infecções Respiratórias/metabolismo , Escarro/análise , Traqueíte/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA